

Clinical & Cost Resource For Specialty Drugs

Case Study: Inappropriate Drug Usage

TPA reviews pharmacy prior authorization through PredictRx reveal innappropriate drug use

Overview

Diversified Group Brokerage, a third party administrator, was handling a claim in which the member suffered from Chronic Respiratory Failure and COPD. The case manager received a call from the member's pharmacy requesting prior authorization on OFEV, a high-cost specialty drug. The TPA requested the member's clinical records to review for medical necessity and consulted PredictRx.

Through PredictRx membership, the client was able to immediately identify the problem: OFEV is an orphan drug whose sole indication is Idiopathic Pulmonary Fibrosis (IPF), which according to the member's medical records as well as the care provider, the member was not diagnosed with. A cross reference with COPD/Chronic Respiratory Failure in PredictDx supported that OFEV is not approved for treatment of this disease.



Due to PredictRx findings, prior authorization for the drug was subsequently denied, preventing the member from taking an extremely high-cost drug that was not approved to treat the disorder.

\$230,000 in Savings

By denying prior authorization for OFEV, the TPA saved the employer group \$231,264 – the average reasonable cost for the drug.

Increased Efficiency

By utilizing PredictRx, the client was able to immediately deduce that OFEV had neither FDA approval nor notable off label uses for the member's condition.

Member Safety

By stopping the delivery of this medication, thanks to proactive case management and the support of PredictRx and PredictDx, the TPA arguably saved this member's life.

